Stichworte
Multiples Myelom ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

315 Suchergebnisse.

E1A05 Multiple Myeloma On-Study Form - Form 2855 NCT00522392

- 06.02.19 - 1 Formular, 6 Itemgruppen, 39 Datenelemente, 1 Sprache
Itemgruppen: Header, Disease Description - Initial Diagnosis, Current Clinical Data, Prior Therapy, Baseline Abnormalities, Comments
E1A05 Multiple Myeloma On-Study Form - Form 2855 NCT00522392 Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3240927B-84FC-4104-E044-0003BA3F9857

E4A03 Prophylactic Treatment and Thrombotic Event Form

- 05.02.19 - 1 Formular, 7 Itemgruppen, 28 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, On Treatment Report Period, Data amendment, Section I - Prophylaxis Treatment, Footer module, Section II - Thrombotic Event(s)
E4A03 Prophylactic Treatment and Thrombotic Event Form Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=2753E114-BE3E-7461-E044-0003BA3F9857

Eligibility Smoldering Multiple Myeloma NCT01441973

- 22.01.19 - 1 Formular, 3 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Criteria, Inclusion Criteria, Exclusion Criteria
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01441973

Eligibility Multiple Myeloma NCT02075996

- 17.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Non-interventional Study With Pomalidomide (Imnovid®); ODM derived from: https://clinicaltrials.gov/show/NCT02075996

Eligibility Multiple Myeloma NCT01241708

- 17.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Criteria, Exclusion Criteria
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01241708

Eligibility Multiple Myeloma NCT01171430

- 17.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
"WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival; ODM derived from: https://clinicaltrials.gov/show/NCT01171430

Eligibility Multiple Myeloma NCT01182233

- 17.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT01182233

Eligibility Multiple Myeloma and Plasma Cell Neoplasm NCT00941720

- 17.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00941720

Eligibility Multiple Myeloma NCT01818752

- 07.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION); ODM derived from: https://clinicaltrials.gov/show/NCT01818752

Eligibility Multiple Myeloma NCT01790737

- 07.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02; ODM derived from: https://clinicaltrials.gov/show/NCT01790737

Eligibility Multiple Myeloma in Relapse NCT01394354

- 07.01.19 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM); ODM derived from: https://clinicaltrials.gov/show/NCT01394354

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

- 27.09.18 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ); ODM derived from: https://clinicaltrials.gov/show/NCT00773838